Bonnie Bassler Buys Shares of Royalty Pharma plc $RPRX

Key Points

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Bonnie Bassler, insider at Royalty Pharma plc ($RPRX), bought 689 shares at an average price of $54.40, for a total transaction of $37,481.60. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Royalty Pharma plc Stock Down 7.9%

Shares of Royalty Pharma plc ($RPRX) traded around $56.07 on Wednesday, down 7.9% for the day.

Last price$56.07
Market cap$27.34B
P/E ratio33.02
Forward P/E10.70
PEG ratio2.19
Beta0.42
52-week low$34.08
52-week high$62.45
50-day MA$58.24
200-day MA$48.76
Current ratio2.80
Quick ratio2.79
Debt-to-equity0.92

Royalty Pharma plc Earnings

EPS (ttm)$1.86
Revenue (ttm)$2.54B
Revenue growth16.50%
Net margin32.02%
Return on equity13.96%
Next earningsNov 4, 2026

Royalty Pharma plc Dividend

Annual dividend$0.94
Dividend yield154%
Payout ratio48.92%
Ex-dividend dateAug 14, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$64.75
High target$70
Low target$61
Analysts covering8

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
CEOMr. Pablo Legorreta
Employees100

Get Royalty Pharma plc alerts

New 13F filings, insider trades, and analyst moves on $RPRX, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.